Top Markets
Coin of the day
EQRx, Inc. EQRx, Inc.

EQRx, Inc.

EQRX
Hisse Senetlerindeki Sıralama #11212
EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating... EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.
Hisse Fiyatı
$2.34
Son senkronizasyon: 2023-11-09
Piyasa Değeri
$728.90M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret EQRx, Inc. (EQRX)

Kategori

EQRx, Inc. (EQRX) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $2.36 - 2023-11-01

Gün sonu en düşük fiyat: $10.24 - 2021-06-01
EQRx, Inc. için hisse fiyatı geçmişi: 2021 - 2026
Yıllık Hisse Fiyatı Performansı
Yıl Performans
2023 -10.70%
2022 -68.78%
2021 0.00%
Benzer şirketler veya rakiplerin hisse fiyatı
Şirket Hisse fiyatı Değişim 1yıl% Ülke
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH